August 01, 2017
Weil advised inVentiv Health, Inc., and selling shareholders Thomas H. Lee Partners and Advent International, in its definitive agreement with INC Research Holdings, Inc. under which the two companies combined in an all-stock merger of equals transaction valued at $4.6 billion. The merger created the second largest biopharmaceutical outsourcing provider focused on creating value for customers, patients, physicians, payers and employees and have an enterprise value of approximately $7.4 billion. The combined company has more than 22,000 employees spanning more than 60 countries, and serves customers in more than 110 countries. Advent International and Thomas H. Lee Partners remained investors in the combined company upon closing of the merger. The transaction closed August 01, 2017.
The Weil team that advised inVentiv was led by Mergers & Acquisitions partner Michael Aiello and included Mergers & Acquisitions partner Sachin Kohli and associates Adam Templeton, Kimberly Thibault, Kelsey Pfleger and Daniel Waxman; Banking & Finance partner Courtney Marcus; Capital Markets partner Heather Emmel; Technology & IP Transactions Head Michael Epstein; Tax partner Mark Hoenig; Executive Compensation & Benefits partner Amy Rubin; Real Estate partner David Herman; Antitrust partner John Scribner; Employment Litigation partner Gary Friedman; Securities Litigation partner Robert Carangelo; Environmental counsel John O’Loughlin; Banking & Finance associates Benton Lewis and Brendan Conley; Capital Markets associate Aman Singh; Technology & IP Transactions associates Lauren Springer and Alexa Rozell; Tax associate Scott Fryman; Executive Compensation & Benefits associates Amanda Rosenblum and John Kleinjan; Real Estate associate Caitlin Steiger; Antitrust associate Jonathan Cheng; Employment Litigation associate Marissa Flood; and Securities Litigation associates Raquel Kellert and Jonnah Hollander.